dabigatran has been researched along with Cirrhosis, Liver in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beyene, K; Chan, AHY; Gong, J; Hayes, M; Munevar Aquite, O; Schauer, C; Wei, H | 1 |
| Chen, Y; Huang, K; Wu, M; Xia, H; Yu, S; Yu, W; Zhou, H | 1 |
| Broniatowska, E; Papuga-Szela, E; Undas, A; Weronska, A | 1 |
| Anstee, QM; Dhar, A; Goldin, RD; Levene, AP; Sadiq, F; Thursz, MR | 1 |
| Adelmeijer, J; Bernal, W; Bos, S; Fisher, C; Kleiss, S; Lisman, T; Patel, VC; Shawcross, DL; Singanayagam, A; Stoy, SH | 1 |
| Cheung, CY; Li, X | 1 |
| Dibiasi, C; Gratz, J; Wiegele, M | 1 |
| Chan, YH; Chang, SH; Chen, SW; Kuo, CF; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Abdel-Bakky, MS; Abo-Saif, AA; Mahmoud, NI; Messiha, BAS; Salehc, IG | 1 |
| Kamphuisen, PW; Lisman, T; Northup, PG; Porte, RJ | 1 |
| Adelmeijer, J; Arshad, F; Blokzijl, H; Lisman, T; Porte, RJ; Potze, W; van den Berg, AP | 1 |
| Adelmeijer, J; Arshad, F; Blokzijl, H; Lisman, T; Meijers, JC; Porte, RJ; Potze, W; van den Berg, AP | 1 |
| Adelmeijer, J; Bos, S; Boyett, SL; Daita, K; Lisman, T; Potze, W; Sanyal, AJ; Siddiqui, MS | 1 |
| Caldwell, SH; Intagliata, NM; Maitland, H; Pellitier, S | 1 |
| Nendaz, M; Perrier, A | 1 |
1 review(s) available for dabigatran and Cirrhosis, Liver
| Article | Year |
|---|---|
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Liver Cirrhosis; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2013 |
14 other study(ies) available for dabigatran and Cirrhosis, Liver
| Article | Year |
|---|---|
Bleeding risk of oral anticoagulants in liver cirrhosis.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Liver Cirrhosis; New Zealand; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; End Stage Liver Disease; Hemorrhage; Humans; Liver Cirrhosis; Portal Vein; Retrospective Studies; Rivaroxaban; Severity of Illness Index; Treatment Outcome; Venous Thrombosis | 2023 |
Reduced‑dose apixaban and dabigatran in patients with advanced liver cirrhosis and venous thromboembolism: a case series.
Topics: Anticoagulants; Dabigatran; Humans; Liver Cirrhosis; Pyrazoles; Pyridones; Venous Thromboembolism | 2021 |
Thrombin and factor Xa link the coagulation system with liver fibrosis.
Topics: Actins; Animals; Antithrombins; Blood Coagulation; Cell Line; Cell Shape; Dabigatran; Disease Models, Animal; Factor Xa; Factor Xa Inhibitors; Gene Expression; Hepatic Stellate Cells; Humans; Hydroxyproline; Liver Cirrhosis; Male; Mice, Inbred C57BL; Procollagen; Receptor, PAR-1; Rivaroxaban; Thrombin; Transforming Growth Factor beta | 2018 |
In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis.
Topics: Adult; Aged; Anticoagulants; Benzimidazoles; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Female; Hemorrhage; Hemostasis; Humans; Liver Cirrhosis; Male; Middle Aged; Plasma; Recombinant Proteins; Rivaroxaban; Thrombin | 2018 |
Dabigatran causing severe acute kidney injury in a patient with liver cirrhosis.
Topics: Acute Kidney Injury; Administration, Intravenous; Antifibrinolytic Agents; Antithrombins; Dabigatran; Humans; Kidney Tubules; Liver Cirrhosis; Male; Middle Aged; Necrosis; Severity of Illness Index; Treatment Outcome; Vitamin K | 2019 |
Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis.
Topics: Aged; Blood Loss, Surgical; Carcinoma, Hepatocellular; Dabigatran; Humans; Infusions, Intravenous; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Mesenteric Vascular Occlusion; Mesenteric Veins; Pyrazoles; Pyridones; Risk Assessment; Thromboembolism; Tranexamic Acid; Venous Thrombosis | 2019 |
Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Taiwan; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2019 |
Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats.
Topics: Animals; Anticoagulants; Biomarkers; Blood Platelets; Carbon Tetrachloride; Clopidogrel; Dabigatran; Liver; Liver Cirrhosis; Male; Oxidative Stress; Rats; Thrombin | 2019 |
Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Diagnostic Tests, Routine; Drug Monitoring; Factor Xa Inhibitors; False Negative Reactions; Female; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Polysaccharides; Prothrombin; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thrombophilia | 2013 |
Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Female; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Thrombin | 2014 |
Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease.
Topics: Adult; Alcoholism; Anticoagulants; Dabigatran; Enoxaparin; Female; Hemostasis; Humans; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrazoles; Pyridones; Thrombosis | 2017 |
Reversal of direct oral anticoagulants for liver transplantation in cirrhosis: A step forward.
Topics: Administration, Intravenous; Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Loss, Surgical; Dabigatran; End Stage Liver Disease; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Preoperative Care; Severity of Illness Index; Treatment Outcome; Venous Thrombosis | 2017 |
[Update in hospital internal medicine (2007): a selection].
Topics: Anti-Bacterial Agents; Anticoagulants; Benzimidazoles; Bone Density Conservation Agents; Community-Acquired Infections; Coronary Disease; Dabigatran; Defibrillators, Implantable; Diabetes Mellitus, Type 2; Fractures, Bone; Heart Failure; Heart Neoplasms; Hip Prosthesis; Hospital Departments; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Internal Medicine; Liver Cirrhosis; Oligosaccharides; Osteoporosis; Peritonitis; Pneumonia, Bacterial; Pulmonary Embolism; Pyridines; Quality of Health Care; Risk Factors; Stroke; Teaching; Tomography, X-Ray Computed; Venous Thrombosis | 2008 |